Literature DB >> 30190906

When to consider alternatives to front-line immune therapies in metastatic melanoma.

Daniel Y Wang1, Douglas B Johnson1.   

Abstract

Entities:  

Keywords:  immunotherapy; melanoma; targeted therapy

Year:  2017        PMID： 30190906      PMCID： PMC6094648          DOI： 10.2217/mmt-2017-0005

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


× No keyword cloud information.
  21 in total

Review 1.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

2.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

3.  A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.

Authors:  Jeffrey A Sosman; James Moon; Ralph J Tuthill; James A Warneke; John T Vetto; Bruce G Redman; P Y Liu; Joseph M Unger; Lawrence E Flaherty; Vernon K Sondak
Journal:  Cancer       Date:  2011-03-31       Impact factor: 6.860

Review 4.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Responses to immune checkpoint inhibitors in nonagenarians.

Authors:  Romany A N Johnpulle; Robert M Conry; Jeffrey A Sosman; Igor Puzanov; Douglas B Johnson
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

7.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Authors:  Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

8.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

Authors:  Stephanie L Goff; Mark E Dudley; Deborah E Citrin; Robert P Somerville; John R Wunderlich; David N Danforth; Daniel A Zlott; James C Yang; Richard M Sherry; Udai S Kammula; Christopher A Klebanoff; Marybeth S Hughes; Nicholas P Restifo; Michelle M Langhan; Thomas E Shelton; Lily Lu; Mei Li M Kwong; Sadia Ilyas; Nicholas D Klemen; Eden C Payabyab; Kathleen E Morton; Mary Ann Toomey; Seth M Steinberg; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2016-05-23       Impact factor: 44.544

9.  Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

Authors:  Bridgette A Kanz; Megan H Pollack; Romany Johnpulle; Igor Puzanov; Leora Horn; Alicia Morgans; Jeffrey A Sosman; Suthee Rapisuwon; R Martin Conry; Zeynep Eroglu; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.